Qualitative Evaluation of Fiducial Markers for Radiotherapy Imaging

被引:43
作者
Chan, Maria F. [1 ]
Cohen, Gil'ad N. [1 ]
Deasy, Joseph O. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY 10065 USA
关键词
radiotherapy; fiducial markers; target motion; IGRT; RADIATION-THERAPY; PROSTATE-CANCER; DOSE PERTURBATIONS; SIMULATION; VISIBILITY; MOTION;
D O I
10.1177/1533034614547447
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate visibility, artifacts, and distortions of various commercial markers in magnetic resonance imaging (MRI), computer tomography (CT), and ultrasound imaging used for radiotherapy planning and treatment guidance. Methods: We compare 2 solid gold markers, 4 gold coils, and 1 polymer marker from 3 vendors. Imaging modalities used were 3-T and 1.5-T GE MRIs, Siemens Sequoia 512 Ultrasound, Phillips Big Bore CT, Varian Trilogy linear accelerator (cone-beam CT [CBCT], on-board imager kilovoltage [OBI-kV], electronic portal imaging device megavoltage [EPID-MV]), and Medtronic O-ARM CBCT. Markers were imaged in a 30 x 30 x 10 cm(3) custom bolus phantom. In one experiment, Surgilube was used around the markers to reduce air gaps. Images were saved in Digital Imaging and Communications in Medicine (DICOM) format and analyzed using an in-house software. Profiles across the markers were used for objective comparison of the markers' signals. The visibility and artifacts/distortions produced by each marker were assessed qualitatively and quantitatively. Results: All markers are visible in CT, CBCT, OBI-kV, and ultrasound. Gold markers below 0.75 mm in diameter are not visible in EPID-MV images. The larger the markers, the more CT and CBCT image artifacts there are, yet the degree of the artifact depends on scan parameters and the scanner itself. Visibility of gold coils of 0.75 mm diameter or larger is comparable across all imaging modalities studied. The polymer marker causes minimal artifacts in CT and CBCT but has poor visibility in EPID-MV. Gold coils of 0.5 mm exhibit poor visibility in MRI and EPID-MV due to their small size. Gold markers are more visible in 3-T T1 gradient-recalled echo than in 1.5-T T1 fast spin-echo, depending on the scan sequence. In this study, all markers are clearly visible on ultrasound. Conclusion: All gold markers are visible in CT, CBCT, kV, and ultrasound; however, only the large diameter markers are visible in MV. When MR and EPID-MV imagers are used, the selection of fiducial markers is not straightforward. For hybrid kV/MV image-guided radiotherapy imaging, larger diameter markers are suggested. If using kV imaging alone, smaller sized markers may be used in smaller sized patients in order to reduce artifacts. Only larger diameter gold markers are visible across all imaging modalities.
引用
收藏
页码:298 / 304
页数:7
相关论文
共 25 条
  • [1] Co-registration of magnetoencephalography with magnetic resonance imaging using bite-bar-based fiducials and surface-matching
    Adjamian, P
    Barnes, GR
    Hillebrand, A
    Holliday, IE
    Singh, KD
    Furlong, PL
    Harrington, E
    Barclay, CW
    Route, PJG
    [J]. CLINICAL NEUROPHYSIOLOGY, 2004, 115 (03) : 691 - 698
  • [2] [Anonymous], J MED PHYS
  • [3] IMAGE-GUIDED RADIOTHERAPY (IGRT) FOR PROSTATE CANCER COMPARING kV IMAGING OF FIDUCIAL MARKERS WITH CONE BEAM COMPUTED TOMOGRAPHY (CBCT)
    Barney, Brandon M.
    Lee, R. Jeffrey
    Handrahan, Diana
    Welsh, Keith T.
    Cook, J. Taylor
    Sause, William T.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 80 (01): : 301 - 305
  • [4] Britton Keith R, 2005, Radiat Med, V23, P14
  • [5] Fiducial markers in prostate for kV imaging: quantification of visibility and optimization of imaging conditions
    Chen, Yu
    O'Connell, John J.
    Ko, Christine J.
    Mayer, Rulon R.
    Belard, Arnaud
    McDonough, James E.
    [J]. PHYSICS IN MEDICINE AND BIOLOGY, 2012, 57 (01) : 155 - 172
  • [6] Dose perturbations and image artifacts caused by carbon-coated ceramic and stainless steel fiducials used in proton therapy for prostate cancer
    Cheung, Joey
    Kudchadker, Rajat J.
    Zhu, X. Ronald
    Lee, Andrew K.
    Newhauser, Wayne D.
    [J]. PHYSICS IN MEDICINE AND BIOLOGY, 2010, 55 (23) : 7135 - 7147
  • [7] de Langen M, 2007, RADIOTHER ONCOL, V84, pS181
  • [8] ERICKSON BJ, 1993, AM J NEURORADIOL, V14, P713
  • [9] DOSIMETRIC IMPACT AND THEORETICAL CLINICAL BENEFITS OF FIDUCIAL MARKERS FOR DOSE ESCALATED PROSTATE CANCER RADIATION TREATMENT
    Gauthier, Isabelle
    Carrier, Jean-Francois
    Beliveau-Nadeau, Dominic
    Fortin, Bernard
    Taussky, Daniel
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 74 (04): : 1128 - 1133
  • [10] Evaluation of different fiducial markers for image-guided radiotherapy and particle therapy
    Habermehl, Daniel
    Henkner, Katrin
    Ecker, Swantje
    Jaekel, Oliver
    Debus, Juergen
    Combs, Stephanie E.
    [J]. JOURNAL OF RADIATION RESEARCH, 2013, 54 : 61 - 68